Therapeutic Strategies for the Clinical Blockade of IL-6/gp130 Signaling

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2011 Sep 2

PMID 21881215

Citations 309

Authors

Simon A Jones

Jurgen Scheller

Stefan Rose-John

Affiliations

Soon will be listed here.

Abstract

The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Citing Articles

The adipokines in oral cancer pathogenesis and its potential as a new therapeutic approach.

Wang X, Wang J, Zhao X, Zhang J, Zhang Y Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40056203 DOI: 10.1007/s00210-025-03939-w.

Sepsis: the evolution of molecular pathogenesis concepts and clinical management.

Feng Z, Wang L, Yang J, Li T, Liao X, Kang Y MedComm (2020). 2025; 6(3):e70109.

PMID: 39991626 PMC: 11847631. DOI: 10.1002/mco2.70109.

Homoharringtonine: mechanisms, clinical applications and research progress.

Wang W, He L, Lin T, Xiang F, Wu Y, Zhou F Front Oncol. 2025; 15:1522273.

PMID: 39949739 PMC: 11821653. DOI: 10.3389/fonc.2025.1522273.

New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.

Nada H, Choi Y, Kim S, Jeong K, Meanwell N, Lee K Signal Transduct Target Ther. 2024; 9(1):341.

PMID: 39638817 PMC: 11621763. DOI: 10.1038/s41392-024-02036-3.

Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.

Shi C, Bopp T, Lo H, Tkaczuk K, Lin J Curr Oncol. 2024; 31(10):5737-5751.

PMID: 39451730 PMC: 11505662. DOI: 10.3390/curroncol31100426.

References

Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S . Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106(8):2627-32. DOI: 10.1182/blood-2004-12-4602. View

Doganci A, Eigenbrod T, Krug N, De Sanctis G, Hausding M, Erpenbeck V . The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest. 2005; 115(2):313-25. PMC: 544603. DOI: 10.1172/JCI22433. View

Jackson C, Giraud A . STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol. 2009; 24(4):505-7. DOI: 10.1111/j.1440-1746.2009.05822.x. View

Nowell M, Richards P, Horiuchi S, Yamamoto N, Rose-John S, Topley N . Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003; 171(6):3202-9. DOI: 10.4049/jimmunol.171.6.3202. View

Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T . Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A. 1996; 93(1):407-11. PMC: 40247. DOI: 10.1073/pnas.93.1.407. View

Lissilaa R, Buatois V, Magistrelli G, Williams A, Jones G, Herren S . Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol. 2010; 185(9):5512-21. DOI: 10.4049/jimmunol.1002015. View

Modur V, Li Y, Zimmerman G, Prescott S, McIntyre T . Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest. 1998; 100(11):2752-6. PMC: 508479. DOI: 10.1172/JCI119821. View

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

Hurst S, Wilkinson T, McLoughlin R, Jones S, Horiuchi S, Yamamoto N . Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14(6):705-14. DOI: 10.1016/s1074-7613(01)00151-0. View

10.

Campbell I, ODonnell K, Lawlor K, Wicks I . Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest. 2001; 107(12):1519-27. PMC: 200197. DOI: 10.1172/JCI12724. View

11.

Stahl E, Raychaudhuri S, Remmers E, Xie G, Eyre S, Thomson B . Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010; 42(6):508-14. PMC: 4243840. DOI: 10.1038/ng.582. View

12.

Screpanti I, Musiani P, Bellavia D, Cappelletti M, Aiello F, Maroder M . Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J Exp Med. 1996; 184(4):1561-6. PMC: 2192807. DOI: 10.1084/jem.184.4.1561. View

13.

Nowell M, Williams A, Carty S, Scheller J, Hayes A, Jones G . Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol. 2008; 182(1):613-22. DOI: 10.4049/jimmunol.182.1.613. View

14.

Jones S, Horiuchi S, Topley N, Yamamoto N, Fuller G . The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001; 15(1):43-58. DOI: 10.1096/fj.99-1003rev. View

15.

Marin V, Montero-Julian F, Gres S, Boulay V, Bongrand P, Farnarier C . The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol. 2001; 167(6):3435-42. DOI: 10.4049/jimmunol.167.6.3435. View

16.

Kremer J, Bloom B, Breedveld F, Coombs J, Fletcher M, Gruben D . The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009; 60(7):1895-905. DOI: 10.1002/art.24567. View

17.

Rose-John S, Scheller J, Elson G, Jones S . Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80(2):227-36. DOI: 10.1189/jlb.1105674. View

18.

Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T . The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989; 169(1):333-8. PMC: 2189201. DOI: 10.1084/jem.169.1.333. View

19.

Chesnokova V, Melmed S . Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology. 2002; 143(5):1571-4. DOI: 10.1210/endo.143.5.8861. View

20.

Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N . Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2000; 268(1):160-7. DOI: 10.1046/j.1432-1327.2001.01867.x. View